Brief: Integragen and Laboratoire Cerba agree to commercialize tumor expression test
08/03/2017 07:03
March 8 (Reuters) - Integragen SA ALINT.PA :
* Integragen and Laboratoire Cerba sign licensing agreement
to commercialize miR-31-3p tumor expression test
* Signing of a licensing agreement allowing Laboratoire
Cerba to develop and provide a test based on Integragen's
proprietary miR-31-3p biomarker
* CEO of Laboratoire Cerba looks forward to making this test
available for clinicians in the first half of 2017 once we have
completed the validation steps in our laboratory
Source text for Eikon: urn:newsml:reuters.com:*:nNDL16hWVt
Further company coverage: ALINT.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))